版本:
中国

BRIEF-Sunesis Pharma announces withdrawal of European MAA for vosaroxin

May 1 Sunesis Pharmaceuticals Inc:

* Sunesis Pharmaceuticals announces withdrawal of European Marketing Authorization Application (MAA) for vosaroxin as a treatment for relapsed/refractory AML

* Sunesis Pharmaceuticals Inc says expect that current cash resources are sufficient to fund company beyond Q1 2018

* Sunesis Pharmaceuticals - significantly reducing investment in AML program & shifting an increasing portion of resources to kinase inhibitor pipeline Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐